November 25, 2017 5:58 AM ET

Biotechnology

Company Overview of Alnylam Pharmaceuticals, Inc.

Executive Profile

Phillip A. Sharp Ph.D.

Co-Founder, Director & Member of the Scientific Advisory Board, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 12 Board Members in 12 organization across 10 different industries.

See Board Relationships
72$543,713

Background

Dr. Phillip A. Sharp, also known as Phil, Ph.D., serves as the President of American Association for the Advancement of Science. Dr. Sharp co-founded Alnylam Pharmaceuticals, Inc. in 2002. He Co-founded Biogen Inc. (formerly Biogen Idec Inc.) in 1978. He co-founded Magen BioSciences, Inc. (formerly PPD Dermatology, Inc.) in 2006. He has been Institute Professor of Center for Cancer Research, Massachusetts Institute of Technology since 1999. He joined the Center for Cancer ...

Corporate Headquarters

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships

Director
Director
Director and Member of Strategic Advisory Board
Director
2002-Present
Co-Founder, Director & Member of the Scientific Advisory Board
2012-Present
Member of Scientific Advisory Board & Director

Education

PhD
University of Illinois-Urbana-Champaign
BA
Union College

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$90,000
Total Calculated Compensation$543,713
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Andrew Rackear J.D.CEO & Secretary
Enzon Pharmaceuticals, Inc.
--
Pascal Soriot CEO & Executive Director
AstraZeneca PLC
$2.4M
Douglas S. Ingram J.D., Esq.President, CEO & Director
Sarepta Therapeutics, Inc.
--
Douglas M. Fambrough III, Ph.D.Co-Founder, Chief Executive Officer, President and Director
Dicerna Pharmaceuticals, Inc.
$490.0K
William Stuart Marshall Ph.D.Co-Founder, Chief Executive Officer, President and Director
Miragen Therapeutics, Inc.
$340.0K
Compensation as of Fiscal Year 2016.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alnylam Pharmaceuticals, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.